Based on positive results from the VISION trial, Pluvicto (lutetium177) was recently FDA approved for men with PSMApositive, castrateresistant prostate cancer after chemotherapy—meaning that metastatic lesions have been discovered on a PSMA PET scan, that the cancer is no longer responding to hormone therapies, and that chemotherapy has already been used. This newly available therapy is providing hope for men who previously would have had very few options. While its current indication is limited, studies are ongoing to determine if there is a benefit to using Pluvicto earlier in the treatment sequence. To learn more about Pluvicto, visit www.hcp.novartis.com/products/pluvicto.

0:08 What is Pluvicto (lutetium177) and when will it be available to patients in the United States?

2:43 Is Pluvicto only available for patients who have hormoneresistant prostate cancer after chemotherapy?

3:34 Is dry mouth from Pluvicto a temporary or permanent side effect?

3:57 Would chemo be stopped to administer Pluvicto? What is its place in the sequence of treatments?

5:16 Do patients have to have lesions discovered by a PSMA PET scan to be eligible for Pluvicto?

6:17 Will insurance cover Pluvicto for oligometastatic disease (a small number of metastases) or will it only be covered for patients with extensive metastases?

8:00 Can any provider capable of providing a PSMA PET scan also able to administer Pluvicto?

Don’t know your stage? Take the quiz: Visit http://www.prostatecancerstaging.org

To learn more about prostate cancer visit http://www.pcri.org
Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: https://pcri.org/join

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) notforprofit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians, for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better individualized care. Feel free to explore our website or call our free helpline at 1 (800) 6417274 with any questions that you have. Our Federal Tax ID # is 954617875 and qualifies for maximum charitable gift deductions by individual donors.

The information on the Prostate Cancer Research Institute's YouTube channel is provided with the understanding that the Institute is not engaged in rendering medical advice or recommendation. The information provided in these videos should not replace consultations with qualified health care professionals to meet your individual medical needs.

#ProstateCancer #Prostate #MarkScholzMD